| Identification | Back Directory | [Name]
Carbamic acid, N-(1-methylethyl)-, (1R,3S)-3-[5-[[[3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]-1H-pyrazol-3-yl]cyclopentyl ester, hydrate (1:1) | [CAS]
2733575-91-0 | [Synonyms]
Carbamic acid, N-(1-methylethyl)-, (1R,3S)-3-[5-[[[3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]-1H-pyrazol-3-yl]cyclopentyl ester, hydrate (1:1) | [Molecular Formula]
C19H30N6O5 | [MOL File]
2733575-91-0.mol | [Molecular Weight]
422.49 |
| Hazard Information | Back Directory | [Uses]
PF-07104091 hydrate is a potent and selective CDK2/cyclin E1 and GSK3β inhibitor, with Kis of 1.16 and 537.81 nM, respectively. PF-07104091 hydrate has anti-tumor activity for cyclin E1-amplified cancers. (patent WO2020157652A2). | [IC 50]
CDK2/cyclin E1: 1.16 nM (Ki); GSK3β: 537.81 nM (Ki) | [References]
[1] Douglas Carl BEHENNA, et al. Cdk2 inhibitors. WO2020157652A2. |
|
|